Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol

References

• Chang Q, Tzeng Y, Stephens D. Meningococcal disease: changes in epidemiology and prevention. Clin Epidemiol. 2012;4:237–45.
   PubMedGoogle Scholar
• Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11(1):17. doi:10.1186/1478-7954-11-17.
   PubMed Web of Science ®Google Scholar
• Hart CA, Thomson AP. Meningococcal disease and its management in children. BMJ (Clinical Research Ed). 2006;333(7570):685–90. doi:10.1136/bmj.38968.683958.AE.
   PubMedGoogle Scholar
• Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. Vaccine. 2019;37:2768–82. doi:10.1016/j.vaccine.2019.04.020.
   PubMed Web of Science ®Google Scholar
• Abad R, Bailey F, Garcia IF, Decheva A, Krizova P, Melillo T, Skoczynska A, Vladimirova N. Meningococcal serogroups and surveillance: a systematic review and survey. J Glob Health. 2019;9:010409. doi:10.7189/jogh.09.010409. PMID: 30603079; PMCID: PMC6304171.
   PubMed Web of Science ®Google Scholar
• Invasive meningococcal disease national surveillance report. Australian Government Deparment of Health; 2018.
   Google Scholar
• Australian government Department of Health. National notifiable disease surveillance reports. Canberra, Australia: Commonwealth of Australia; 2019.
   Google Scholar
• Beeslaar J, Absalon J, Balmer P, Srivastava A, Maansson R, York LJ, Perez JL. Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults. Vaccine. 2018;36(28):4004–13. doi:10.1016/j.vaccine.2018.05.060.
   PubMed Web of Science ®Google Scholar
• Marshall HLN, Flood L, Phillips P on behalf of the SA meningococcal B expert working group group introduction of the first state-wide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia. MJA. 2019 (In Press).
   Google Scholar
• Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C, White JM, Borrow R, Ramsay ME, Ladhani SN, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388(10061):2775–82. doi:10.1016/S0140-6736(16)31921-3.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Andrews N, Parikh SR, Campbell H, White J, Edelstein M, Bai X, Lucidarme J, Borrow R, Ramsay ME, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–17. doi:10.1056/NEJMoa1901229.
   PubMed Web of Science ®Google Scholar
• Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F, Black S. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet. 2017;390(10102):1603–10. doi:10.1016/S0140-6736(17)31449-6.
   PubMed Web of Science ®Google Scholar
• Vincent LR, Jerse AE. Biological feasibility and importance of a gonorrhea vaccine for global public health. Vaccine. 2019 Nov 28;37(50):7419–26.. doi:10.1016/j.vaccine.2018.02.081 Epub 2018 Apr 18. PMID: 29680200; PMCID: PMC6892272.
   Web of Science ®Google Scholar
• Ageing; DoHa. Notification Rate of Gonococcal infection, received from State and Territory health authorities in the period of 1991 to 2019 and year-to-date notifications for 2020 [Internet].
   Google Scholar
• Pérez O, Del Campo J, Cuello M, González E, Nuñez N, Cabrera O, Llanes R, Acevedo R, Zayas C, Balboa J, et al. Mucosal approaches in Neisseria vaccinology. VacciMonitor. 2009;18:53–55.
   Google Scholar
• Ochoa-Azze RF. Cross-protection induced by VA-MENGOC-BC(R) vaccine. Hum Vaccin Immunother. 2018;14:1064–68. doi:10.1080/21645515.2018.1438028.
   PubMed Web of Science ®Google Scholar
• Longtin J, Dion R, Simard M, Betala Belinga JF, Longtin Y, Lefebvre B, Labbé AC, Deceuninck G, De Wals P. Possible impacts of wide-scale vaccination against serogroup B Neisseria meningitidis on gonorrhoea incidence rates in one region of Quebec, Canada.Open Forum Infectious Diseases 2017;4(Suppl 1):S734–S735. doi:10.1093/ofid/ofx180.002.
   Google Scholar
• Tinsley CR, Nassif X. Analysis of the genetic differences between Neisseria meningitidis and Neisseria gonorrhoeae: two closely related bacteria expressing two different pathogenicities. Proc Natl Acad Sci U S A. 1996;93:11109–14. doi:10.1073/pnas.93.20.11109.
   PubMed Web of Science ®Google Scholar
• Semchenko EA, Tan A, Borrow R, Seib KL. The serogroup B meningococcal vaccine bexsero elicits antibodies to neisseria gonorrhoeae. Clin Infect Dis. 2019;69:1101–11. doi:10.1093/cid/ciy1061.
   PubMed Web of Science ®Google Scholar
• Marshall HS, McMillan M, Koehler A, Lawrence A, MacLennan JM, Maiden MCJ, Ramsay M, Ladhani SN, Trotter C, Borrow R, et al. B Part of It protocol: a cluster randomised controlled trial to assess the impact of 4CMenB vaccine on pharyngeal carriage of Neisseria meningitidis in adolescents. BMJ Open. 2018;8(7):e020988. doi:10.1136/bmjopen-2017-020988.
   PubMed Web of Science ®Google Scholar
• Marshall HS, McMillan M, Koehler AP, Lawrence A, Sullivan TR, MacLennan JM, Maiden MCJ, Ladhani SN, Ramsay ME, Trotter C, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382(4):318–27. doi:10.1056/NEJMoa1900236.
   PubMed Web of Science ®Google Scholar
• Zurynski Y, McIntyre P, Booy R, Elliott EJ. Paediatric active enhanced disease surveillance: a new surveillance system for Australia. J Paediatr Child Health. 2013;49:588–94. doi:10.1111/jpc.12282.
   PubMed Web of Science ®Google Scholar
• Marshall H, McMillan M, Wang B, Booy R, Afzali H, Buttery J, Blyth CC, Richmond P, Shaw D, Gordon D, et al. AMEND study protocol: a case-control study to assess the long-term impact of invasive meningococcal disease in Australian adolescents and young adults. BMJ Open. 2019;9:e032583. doi:10.1136/bmjopen-2019-032583.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15:301–09. doi:10.1016/S1473-3099(14)71081-3. Epub 2015 Feb 3. PMID: 25656600; PMCID: PMC4876855.
   PubMed Web of Science ®Google Scholar
• Farrington CP. Estimation of vaccine effectiveness using the screening method. Int J Epidemiol. 1993;22:742–46. doi:10.1093/ije/22.4.742.
   PubMed Web of Science ®Google Scholar
• Quinn HE, Gidding HF, Marshall HS, Booy R, Elliott EJ, Richmond P, Crawford N, McIntyre PB, Macartney KK. Varicella vaccine effectiveness over 10 years in Australia; moderate protection from 1-dose program. J Infect. 2019;78(3):220–25. doi:10.1016/j.jinf.2018.11.009.
   PubMed Web of Science ®Google Scholar
• Brehony C, Rodrigues CMC, Borrow R, Smith A, Cunney R, Moxon ER, Maiden MCJ. Distribution of Bexsero(R) Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: implications for immunisation. Vaccine. 2016;34:4690–97. doi:10.1016/j.vaccine.2016.08.015.
   PubMed Web of Science ®Google Scholar
• Medini D, Stella M, Wassil J. MATS: global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine. 2015;33:2629–36. doi:10.1016/j.vaccine.2015.04.015.
   PubMed Web of Science ®Google Scholar
• Nissen M ST, Whiley D, Smith HV, Rockett R, Jennison A, Doyle C, Graham R, Gilchrist S, Frosi G, Orlandi L, et al. Use of the Meningococcal Antigen Typing System (MATS) to assess the australian meningococcal strain coverage with a multicomponent serogroup B vaccine. 20th International Pathogenic Neisseria Conference (IPNC). Würzburg, Germany; 2016 September 4–9; Manchester (UK). p. 257.
   Google Scholar
• Wang B, Santoreneos R, Afzali H, Giles L, Marshall H. Costs of invasive meningococcal disease: a global systematic review. PharmacoEconomics; 2018 Oct;36(10):1201–22. doi:10.1007/s40273-018-0679-5. PMID: 29948965.
   Google Scholar
• Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford university press; 2015. https://books.google.co.uk/books?id=lvWACgAAQBAJ
   Google Scholar
• Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (version 5.0). Canberra, Australia: Australian Government Department of Health and Ageing; 2016.
   Google Scholar
• van den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69(Suppl 1):i89–91. doi:10.1136/ard.2009.117150.
   PubMed Web of Science ®Google Scholar
• Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14:171–89. doi:10.1016/0167-6296(94)00044-5.
   PubMed Web of Science ®Google Scholar
• Kigozi J, Jowett S, Lewis M, Barton P, Coast J. Estimating productivity costs using the friction cost approach in practice: a systematic review. Eur J Health Econ. 2016;17:31–44. doi:10.1007/s10198-014-0652-y.
   PubMed Web of Science ®Google Scholar